[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573055":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":10,"centralContacts":30,"locations":39,"responsibleParty":57,"collaborators":59,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":10,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Gulbenkian Institute for Molecular Medicine","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group",null,"Healthy participants with a negative colonoscopy result",[13],"Other: No intervention: observational study",{"label":15,"type":10,"description":16,"interventionNames":17},"Colorectal cancer","Participants with colorectal cancer diagnosis confirmed by colonoscopy",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Low-risk polyps","Participants with positive colonoscopy and detection of low-risk adenomas",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"High-risk polyps","Participants with positive colonoscopy and detection of high-risk adenomas",[13],[27],{"type":6,"name":28,"description":28,"armGroupLabels":29,"otherNames":10},"No intervention: observational study",[15,9,23,19],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},"Ana S Almeida, PhD","CONTACT","+351 217999411","ana.almeida@gimm.pt",{"name":37,"role":33,"phone":34,"phoneExt":10,"email":38},"Madalena Reis","madalena.reis@gimm.pt",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Lisbon","Lisbon District","1649-028","Portugal","PT",{"type":48,"coordinates":49},"Point",[50,51],-9.1498,38.72509,{"lat":51,"lon":50},[54,55],{"name":37,"role":33,"phone":34,"phoneExt":10,"email":38},{"name":32,"role":56,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[60,63,65],{"name":61,"class":62},"Hospital CUF Descobertas, Lisbon, Portugal","UNKNOWN",{"name":64,"class":62},"CUF Tejo Hospital",{"name":66,"class":62},"Hospital da Luz Lisboa, Portugal","100573055","improving-colorectal-cancer-early-screening-in-portugal-identification-of-gut-microbiome-biomarkers-in-stool-gutbiome-pt-100573055",false,"NCT06741293","Improving Colorectal Cancer Early Screening in Portugal: Identification of Gut Microbiome Biomarkers in Stool (GUTBIOME-PT)","Improving Colorectal Cancer Early Screening in Portugal: Identification and Validation of Biomarkers of Gut Microbiome in Stool","GUTBIOME-PT","Inclusion Criteria:\n\n* Ability to provide written informed consent and comply with study procedures\n* Reside in the Lisbon Metropolitan Area,, Portugal\n* Age from 40 to 74 years\n\nExclusion Criteria:\n\n* Age \\\u003C 40 years or ≥ 75 years\n* Unable to provide informed consent\n* Refusal to provide stool samples\n* Active oncological disease\n* Personal history of CRC\n* Personal history of colon adenomas removed in the last 24 months\n* First-degree family history of CRC\n* Previous diagnosis of inflammatory bowel disease (ulcerative colitis, Crohn's disease or indeterminate colitis), inflammatory bowel syndrome, persistent and infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhoea of unknown aetiology or recurrent infection by Clostridioides difficile\n* Severe cardiovascular or heart diseases with medical diagnosis\n* Severe renal failure requiring hemodialysis\n* Severe lung disease\n* Pregnancy",true,"ALL","40 Years","74 Years",{"count":80,"type":81},30000,"ESTIMATED","OBSERVATIONAL","Colorectal cancer (CRC) is a major public health problem, responsible for 2 million new cases and almost 1 million deaths annually worldwide. In Portugal, as of 2022, CRC is the most common cancer, with 10,575 new cases reported, and the second leading cause of cancer-related mortality, accounting for 4,809 deaths (approximately 14% of all cancer-related deaths). In recent years, there has been an alarming increase in the incidence and mortality of CRC in people \\\u003C50 years of age.\n\nEarly detection is crucial, as survival rates decline sharply from 90% when detected early to just 10% in advanced stages. Non-invasive diagnostic tests, such as the Faecal Immunochemical Test (FIT), have a low sensitivity for early-stage lesions and a high rate of false positives. Therefore, there is an urgent need to improve non-invasive diagnostic methods for the early detection of CRC, as effective screening can prevent it by detecting and removing premalignant lesions.\n\nRecent studies suggest that an altered gut microbiota may confer susceptibility to certain types of cancer. Interestingly, the gut microbiota of patients with adenomas or CRC differs from that of healthy individuals. This study aims to identify gut microbiome biomarkers in faecal samples associated with CRC and\u002For high-risk adenomas to improve early detection.",[85,86,87],"Colorectal Cancer Screening","Colorectal Cancer (CRC)","Microbiome",[89,90,91,92,93],"colorectal cancer","microbiome","colorectal cancer screening","biomarkers","metagenomics","2026-05-11",{"date":96,"type":97},"2026-05-14","ACTUAL",{"date":99,"type":97},"2023-11-28",{"date":101,"type":81},"2029-11-28",{"name":5,"class":6},1]